The potential utility of tight junction regulation in celiac disease: Focus on larazotide acetate

Therapeutic Advances in Gastroenterology

Volumn 9, Issue 1, 2016, Pages 37-49

  Khaleghi, Shahryar ^a   Ju, Josephine M ^a   Lamba, Abhinav ^a   Murray, Joseph A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Caco 2 cells; gliadin; gluten free diet; intestinal integrity; paracellular permeability; zonulin

Indexed keywords

ACTIN; AT 1002; GAMMA INTERFERON; GLIADIN; LARAZOTIDE; LINACLOTIDE; PEPTIDE DERIVATIVE; PLACEBO; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CELIAC DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; GLUTEN FREE DIET; HEADACHE; HUMAN; INTESTINE MUCOSA PERMEABILITY; MULTIPLE DRUG DOSE; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; QUALITY OF LIFE; REVIEW; SINGLE DRUG DOSE; TIGHT JUNCTION; TREATMENT RESPONSE;

EID: 84951755788     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X15616576     Document Type: Review

References (72)

1. Arrieta M. Bistritz L. Meddings J. (2006) Alterations in intestinal permeability. Gut 55: 1512–1520.
2. Batt R. Carter M. McLean L. (1984) Morphological and biochemical studies of a naturally occurring enteropathy in the Irish setter dog: a comparison with coeliac disease in man. Res Vet Sci 37: 339–346.
3. Bjarnason I. Macpherson A. Hollander D. (1995) Intestinal permeability: an overview. Gastroenterology 108: 1566–1581.
4. Boivin M. Roy P. Bradley A. Kennedy J. Rihani T. Ma T. (2009) Mechanism of interferon-gamma-induced increase in T 84 intestinal epithelial tight junction. J Interferon Cytokine Res 29: 45–54.
5. Canil C. Rosenshine I. Ruschkowski S. Donnenberg M. Kaper J. Finlay B. (1993) Enteropathogenic Escherichia coli decreases the transepithelial electrical resistance of polarized epithelial monolayers. Infect Immun 61: 2755–2762.
6. Catassi C. Fabiani E. Iacono G. D'Agate C. Francavilla R. Biagi F. et al. (2007) A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 85: 160–166.
7. Chey W. Lembo A. Lavins B. Shiff S. Kurtz C. Currie M. et al. (2012) Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 107: 1702–1712.
8. Chiba H. Osanai M. Murata M. Kojima T. Sawada N. (2008) Transmembrane proteins of tight junctions. Biochim Biophys Acta 1778: 588–600.
9. Clemente M. de Virgiliis S. Kang J. Macatagney R. Musu M. Di Pierro M. et al. (2003) Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut 52: 218–223.
10. Collin P. Maki M. Kaukinen K. (2004) It is the compliance, not milligrams of gluten, that is essential in the treatment of celiac disease. Nutr Rev 62: 490; author reply, 491.
11. Demeo M. Mutlu E. Keshavarzian A. Tobin M. (2002) Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol 34: 385–396.
12. Demin O. Smirnov S. Sokolov V. Cucurull-Sanchez L. Pichardo-Almarza C. Flores M. et al. (2013) Modeling of celiac disease immune response and the therapeutic effect of potential drugs. BMC Syst Biol 7: 56.
13. Fanning A. van Itallie C. Anderson J. (2012) Zonula occludens-1 and -2 regulate apical cell structure and the zonula adherens cytoskeleton in polarized epithelia. Mol Biol Cell 23: 577–590.
14. Fasano A. Berti I. Gerarduzzi T. Not T. Colletti R. Drago S. et al. (2003) Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 163: 286–292.
15. Fasano A. Not T. Wang W. Uzzau S. Berti I. Tommasini A. et al. (2000) Zonulin, a newly discovered modulator of intestinal permeability and its expression in coeliac disease. Lancet 355: 1518–1519.
16. Fasano A. Paterson B. (2012) Materials and methods for the treatment of celiac disease. US Patent 20120076861 A1.
17. Furuse M. Hata M. Furuse K. Yoshida Y. Haratake A. Sugitani Y. et al. (2002) Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 156: 1099–1111.
18. Furuse M. Hirase T. Itoh M. Nagafuchi A. Yonemura S. Tsukita S. (1993) Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 123: 1777–1788.
19. Gonzalez-Mariscal L. Contreras R. Bolivar J. Ponce A. Chavez D.e. Ramirez B. Cereijido M. (1990) Role of calcium in tight junction formation between epithelial cells. Am J Physiol 259: C978–C986.
20. Gopalakrishnan S. Durai M. Kitchens K. Tamiz A. Somerville R. Ginski M. et al. (2012 a) Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides 35: 86–94.
21. Gopalakrishnan S. Pandey N. Tamiz A. Vere J. Carrasco R. Somerville R. et al. (2009) Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer. Int J Pharm 365: 121–130.
22. Gopalakrishnan S. Tripathi A. Tamiz A. Alkan S. Pandey N. (2012 b) Larazotide acetate promotes tight junction assembly in epithelial cells. Peptides 35: 95–101.
23. Gumbiner B. Stevenson B. Grimaldi A. (1988) The role of the cell adhesion molecule uvomorulin in the formation and maintenance of the epithelial junctional complex. J Cell Biol 107: 1575–1587.
24. Hall E. Batt R. (1991) Abnormal permeability precedes the development of a gluten sensitive enteropathy in Irish setter dogs. Gut 32: 749–753.
25. Hall N. Rubin G. Charnock A. (2013) Intentional and inadvertent non-adherence in adult coeliac disease. A cross-sectional survey. Appetite 68: 56–62.
26. Hartsock A. Nelson W. (2008) Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta 1778: 660–669.
27. Heyman M. Menard S. (2009) Pathways of gliadin transport in celiac disease. Ann N Y Acad Sci 1165: 274–278.
28. Hollander D. (1992) The intestinal permeability barrier. A hypothesis as to its regulation and involvement in Crohn's disease. Scand J Gastroenterol 27: 721–726.
29. Johnston J. Kurtz C. Drossman D. Lembo A. Jeglinski B. Macdougall J. et al. (2009) Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 104: 125–132.
30. Kelly C. Green P. Murray J. Dimarino A. Colatrella A. Leffler D. et al. (2013) Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther 37: 252–262.
31. Lammers K. Lu R. Brownley J. Lu B. Gerard C. Thomas K. et al. (2008) Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology 135: 194–204.
32. Lanzini A. Lanzarotto F. Villanacci V. Mora A. Bertolazzi S. Turini D. et al. (2009) Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment Pharmacol Ther 29: 1299–1308.
33. Lee S. Lo W. Memeo L. Rotterdam H. Green P. (2003) Duodenal histology in patients with celiac disease after treatment with a gluten-free diet. Gastrointest Endosc 57: 187–191.
34. Leffler D. Kelly C. Abdallah H. Colatrella A. Harris L. Leon F. et al. (2012) A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol 107: 1554–1562.
35. Leffler D. Kelly C. Green P. Fedorak R. Dimarino A. Perrow W. et al. (2015) Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology 148: 1311–1319.
36. Lu R. Wang W. Uzzau S. Vigorito R. Zielke H. Fasano A. (2000) Affinity purification and partial characterization of the zonulin / zonula occludens toxin (Zot) receptor from human brain. J Neurochem 74: 320–326.
37. Madara J. Barenberg D. Carlson S. (1986) Effects of cytochalasin D on occluding junctions of intestinal absorptive cells: further evidence that the cytoskeleton may influence paracellular permeability and junctional charge selectivity. J Cell Biol 102: 2125–2136.
38. Mankertz J. Schulzke J. (2007) Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol 23: 379–383.
39. Matysiak-Budnik T. Moura I. Arcos-Fajardo M. Le Breton C. Menard S. Candalh C. et al. (2008) Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med 205: 143–154.
40. Menard S. Le Breton C. Schumann M. Matysiak-Budnik T. Dugave C. Bouhnik Y. et al. (2012) Paracellular versus transcellular intestinal permeability to gliadin peptides in active celiac disease. Am J Pathol 180: 608–615.
41. Midhagen G. Hallert C. (2003) High rate of gastrointestinal symptoms in celiac patients living on a gluten-free diet: controlled study. Am J Gastroenterol 98: 2023–2026.
42. Mitic L. van Itallie C. Anderson J. (2000) Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. Am J Physiol Gastrointest Liver Physiol 279: G250–G254.
43. Molberg O. Solheim Flaete N. Jensen T. Lundin K. Arentz-Hansen H. Anderson O. et al. (2003) Intestinal T-cell responses to high-molecular-weight glutenins in celiac disease. Gastroenterology 125: 337–344.
44. Mustalahti K. Lohiniemi S. Collin P. Vuolteenaho N. Laippala P. Maki M. (2002) Gluten-free diet and quality of life in patients with screen-detected celiac disease. Eff Clin Pract 5: 105–113.
45. Nilsen E. Jahnsen F. Lundin K. Johansen F. Fausa O. Sollid L. et al. (1998) Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. Gastroenterology 115: 551–563.
46. Paterson B. Lammers K. Arrieta M. Fasano A. Meddings J. (2007) The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Curr Opin Gastroenterol 26: 757–766.
47. Piche T. Barbara G. Aubert P. Bruley Des Varannes S. Dainese R. Nano J. et al. (2009) Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 58: 196–201.
48. Pinier M. Verdu E. Nasser-Eddine M. David C. Vezina A. Rivard N. et al. (2009) Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology 136: 288–298.
49. Pruessner H. (1998) Detecting celiac disease in your patients. Am Fam Physician 57: 1023–1034, 1039–1041.
50. Rao A. Camilleri M. Eckert D. Busciglio I. Burton D. Ryks M. et al. (2011) Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls. Am J Physiol Gastrointest Liver Physiol 301: G919–G928.
51. Rashtak S. Murray J. (2012) Review article: coeliac disease, new approaches to therapy. Aliment Pharmacol Ther 35: 768–781.
52. Rubio-Tapia A. Murray J. (2010) Classification and management of refractory coeliac disease. Gut 59: 547–557.
53. Rubio-Tapia A. Rahim M. See J. Lahr B. Wu T. Murray J. (2010) Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol 105: 1412–1420.
54. Sainsbury K. Mullan B. Sharpe L. (2013) Reduced quality of life in coeliac disease is more strongly associated with depression than gastrointestinal symptoms. J Psychosom Res 75: 135–141.
55. Sander G. Cummins A. Henshall T. Powell B. (2005) Rapid disruption of intestinal barrier function by gliadin involves altered expression of apical junctional proteins. FEBS Lett 579: 4851–4855.
56. Schmitz H. Fromm M. Bentzel C. Scholz P. Detjen K. Mankertz J. et al. (1999) Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J Cell Sci 112 ( Pt 1): 137–146.
57. Schulzke J. Bentzel C. Schulzke I. Riecken E. Fromm M. (1998) Epithelial tight junction structure in the jejunum of children with acute and treated celiac sprue. Pediatr Res 43: 435–441.
58. Silva M. Jury J. Sanz Y. Wiepjes M. Huang X. Murray J. et al. (2012) Increased bacterial translocation in gluten-sensitive mice is independent of small intestinal paracellular permeability defect. Dig Dis Sci 57: 38–47.
59. Sollid L. (2002) Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2: 647–655.
60. Thomas K. Sapone A. Fasano A. Vogel S. (2006) Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in Celiac disease. J Immunol 176: 2512–2521.
61. Tibble J. Sigthorsson G. Bridger S. Fagerhol M. Bjarnason I. (2000) Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119: 15–22.
62. Ulluwishewa D. Anderson R. Mcnabb W. Moughan P. Wells J. Roy N. (2011) Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr 141: 769–776.
63. US Food and Drug Administration Rule (2013) Food Labeling; Gluten-Free Labeling of Foods, 78 Fed. Reg, 47,154 (August 05, 2013). Available at: https://federalregister.gov/a/2013-18813
64. van der Merwe J. Hollenberg M. Macnaughton W. (2008) EGF receptor transactivation and MAP kinase mediate proteinase-activated receptor-2-induced chloride secretion in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 294: G441–G451.
65. van Elburg R. Uil J. Mulder C. Heymans H. (1993) Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease. Gut 34: 354–357.
66. van Itallie C. Anderson J. (2011) Measuring size-dependent permeability of the tight junction using PEG profiling. Methods Mol Biol 762: 1–11.
67. Visser J. Rozing J. Sapone A. Lammers K. Fasano A. (2009) Tight junctions, intestinal permeability and autoimmunity: celiac disease and type 1 diabetes paradigms. Ann N Y Acad Sci 1165: 195–205.
68. Wang F. Schwarz B. Graham W. Wang Y. Su L. Clayburgh D. et al. (2006) IFN-gamma-induced TNFR 2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology 131: 1153–1163.
69. Watts T. Berti I. Sapone A. Gerarduzzi T. Not T. Zielke R. et al. (2005) Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc Natl Acad Sci U S A 102: 2916–2921.
70. Wyatt J. Oberhuber G. Pongratz S. Puspok A. Moser G. Novacek G. et al. (1997) Increased gastric and intestinal permeability in patients with Crohn's disease. Am J Gastroenterol 92: 1891–1896.
71. Yu A. (2011) Electrophysiological characterization of claudin ion permeability using stably transfected epithelial cell lines. Methods Mol Biol 762: 27–41.
72. Zhou Q. Souba W. Croce C. Verne G. (2010) MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut 59: 775–784.